Aprea Therapeutics, Inc. filed a Form 8-K on November 4, 2026, reporting its financial results for the three and nine months ended September 30, 2026, and providing an operational update for the same period.
Clear Secure, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting third-quarter and nine-month financial results.
Vishay Precision Group, Inc. filed a Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter and nine fiscal months ended October 3, 2026, reporting a net loss attributable to VPG stockholders of $1,480 thousand for the nine-month period.
NNN REIT, Inc. released its third-quarter and nine-month financial and operating results on November 4, 2026, covering the period ended September 30, 2026, reporting growth in Core FFO, annualized base rent, and portfolio occupancy.
WaFd, Inc. filed a definitive proxy statement (DEFM14A) on November 4, 2026, asking shareholders to approve the issuance of WaFd common stock in connection with its proposed merger with EverBank Financial Corp, with a special meeting scheduled for December 16, 2026.
Vertiv Holdings Co. announced a three-year strategic agreement with Infineon Technologies AG on November 4, 2026, covering supply of silicon and silicon carbide power semiconductors for Vertiv's global power product portfolio.
TeraWulf Inc. filed a Form 8-K with the SEC on November 4, 2026, disclosing that its subsidiary Raylan Data LLC entered into three Credit Support Agreements with Google LLC to backstop certain obligations of Anthropic, PBC under existing 20-year data center leases at TeraWulf's …
Aberdeen Group plc and its subsidiary abrdn Inc. filed an amended beneficial ownership statement with the SEC on November 4, 2026, disclosing a combined 7.03% stake in Equillium, Inc. (NASDAQ:EQ) as of September 30, 2026.
Harmony Biosciences Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting net product revenue of $268.9 million for the third quarter and net income of $48.2 million.
Septerna, Inc. filed a Form 8-K on November 4, 2026, disclosing that the company selected SEP-204 as a development candidate for Graves' disease and thyroid eye disease (TED) and reported preclinical data at the 2026 American Thyroid Association Annual Meeting.